| 000 | 01920 a2200565 4500 | ||
|---|---|---|---|
| 005 | 20250517091203.0 | ||
| 264 | 0 | _c20171018 | |
| 008 | 201710s 0 0 eng d | ||
| 022 | _a2352-3026 | ||
| 024 | 7 |
_a10.1016/S2352-3026(15)00247-1 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBerthon, Céline | |
| 245 | 0 | 0 |
_aBromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. _h[electronic resource] |
| 260 |
_bThe Lancet. Haematology _cApr 2016 |
||
| 300 |
_ae186-95 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAcetanilides _xadministration & dosage |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aCanada |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFrance |
| 650 | 0 | 4 |
_aHeterocyclic Compounds, 3-Ring _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Myeloid, Acute _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aUnited Kingdom |
| 700 | 1 | _aRaffoux, Emmanuel | |
| 700 | 1 | _aThomas, Xavier | |
| 700 | 1 | _aVey, Norbert | |
| 700 | 1 | _aGomez-Roca, Carlos | |
| 700 | 1 | _aYee, Karen | |
| 700 | 1 | _aTaussig, David Christopher | |
| 700 | 1 | _aRezai, Keyvan | |
| 700 | 1 | _aRoumier, Christophe | |
| 700 | 1 | _aHerait, Patrice | |
| 700 | 1 | _aKahatt, Carmen | |
| 700 | 1 | _aQuesnel, Bruno | |
| 700 | 1 | _aMichallet, Mauricette | |
| 700 | 1 | _aRecher, Christian | |
| 700 | 1 | _aLokiec, François | |
| 700 | 1 | _aPreudhomme, Claude | |
| 700 | 1 | _aDombret, Hervé | |
| 773 | 0 |
_tThe Lancet. Haematology _gvol. 3 _gno. 4 _gp. e186-95 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S2352-3026(15)00247-1 _zAvailable from publisher's website |
| 999 |
_c25911623 _d25911623 |
||